You're reading the free version. Trader adds the live tape and alerts.
Start tracking
SYRE Sale Disclosure
Burrows Scott L · SEC Form 4 · Filed Oct 2, 2026
Sale
Calculated transaction value
$53.44K
Burrows Scott L Chief Financial Officer
SYRE
Spyre Therapeutics
SYRE
Transaction date
Oct 1, 2026
Public filing date
Oct 2, 2026
Filing lag
Filed 1 day later
SYRE daily price context
Close on/before transaction
$89.93
Oct 1, 2026
First close after public filing
$92.72
Oct 5, 2026
30-day return after filing
+3.01%
Through Nov 2, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 600 shares @ $89.07
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001636282-26-000117
Filing cohort
Transactions in this filing
Showing 10 of 10
Trades
10
Issuers
1
Estimated value
$2.62M
Buys / sales
0 / 6
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Spyre Therapeutics, Inc. SYRE | Sale | Oct 1, 2026 | $135.41K |
| Spyre Therapeutics, Inc. SYRE | Exercise | Oct 1, 2026 | $0 |
| Spyre Therapeutics, Inc. SYRE | Sale | Oct 1, 2026 | $21.43K |
| Spyre Therapeutics, Inc. SYRE | Sale | Oct 1, 2026 | $285.45K |
| Spyre Therapeutics, Inc. SYRE | Exercise | Oct 1, 2026 | $108.75K |
| Spyre Therapeutics, Inc. SYRE | Sale | Oct 1, 2026 | $193.03K |
| Spyre Therapeutics, Inc. SYRE Current | Sale | Oct 1, 2026 | $53.44K |
| Spyre Therapeutics, Inc. SYRE | Exercise | Sep 30, 2026 | $0 |
| Spyre Therapeutics, Inc. SYRE | Sale | Sep 30, 2026 | $1.57M |
| Spyre Therapeutics, Inc. SYRE | Exercise | Sep 30, 2026 | $253.75K |